Compare Amgen, Inc. (AMGN) vs Ecolab Inc. (ECL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Ecolab Inc. — how do they compare? Amgen, Inc. trades at $364.5 (market cap $196.12B), while Ecolab Inc. trades at $274.31 (market cap $77.20B). The key difference: Amgen, Inc. is far larger — about 2.5× Ecolab Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | ECL | |
|---|---|---|
Market Cap | $196.12B | $77.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $308.35 |
52-Week Low | $271.18 | $245.73 |
Enterprise Value | $241.41B | $85.95B |
Dividend Yield | 2.77% | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ECL trades at $274.31, up 0.47% on the day, with a bullish technical signal and strong analyst support. The company reported $16.08B in 2025 revenue, $2.08B net income, and maintains robust profitability with a 12.8% net margin and 22.31% ROE. Recent news highlights the $4.75B CoolIT acquisition, expanding its AI cooling portfolio, and a consistent dividend payout.
Outlook remains positive with a consensus price target of $327.43, implying 19% upside, though risks include rising costs and negative cash flow trends. Earnings growth and digital expansion are key catalysts, but investors should monitor execution on acquisitions and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
